154247
Enhanced External Counterpulsation as a Non-pharmacological Treatment for Patients With Severe and Moderate Ventilation Disorders
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07075835/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт.
- Возраст участников: 35–74 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 80 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 07.2027.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 2 · невключение: 18
Критерии включения
- Verified severe (30% < forced expiratory volume in 1 second < 49% or lung diffusion capacity < 40%) and moderate (50% < forced expiratory volume in 1 second < 59% or lung diffusion capacity 40-60%) ventilation disorders in patients with different chronic lung diseases who are on optimal basic therapy (according to current clinical guidelines) and are in a stable state of respiratory disease (1 month without exacerbations)
- Signed informed voluntary consent to participate in the study
Критерии невключения
- A history of thrombophlebitis and/or phlebitis
- Thoracic or abdominal aortic aneurysm
- Severe pathology of the valvular heart (Area of orifice in stenoses: Aortic and tricuspid valves: < 1.0 cm²; Mitral valve: < 1.5 cm². Pulmonary valve: pressure gradient between right ventricle and pulmonary artery > 50 mmHg; In case of insufficiency, regurgitation of grade 3-4 according to echocardiography)
- Pregnancy
- High pulmonary hypertension (grade 2-3; >45 mmHg)
- Catheterization cardiac arrest performed within 2-4 weeks before the study
- Tachyarrhythmias (device Myocard-12)
- Uncontrolled arterial hypertension (>180/110 mmHg when treated with 3 drugs, one of which is a diuretic)
- Hemorrhagic conditions critical arterial ischemia of the lower extremities (Stages 3 and 4 of chronic arterial insufficiency of the lower extremities according to the Pokrovsky-Fontaine classification are patients with pain at rest and with trophic or infectious-inflammatory changes in the tissues of the extremities
- Dilatation of the heart cavities (device Philips iU22 Ultrasound)
- Ejection fraction <50% (device Philips iU22 Ultrasound)
- Level of NT-pro BNP > 125 pg/ml
- A history of myocardial infarction
- Severe renal (glomerular filtration rate <30 ml/min/1,73 m2) failure
- Hepatic failure (B and C on the Child-Pugh scale)
- Poor tolerance of the procedure (side effects that disrupt the patient's condition and prevent the continuation of procedures (local: hyperemia, pain, and itching in the area of the cuff application; systemic: hypertensive reaction, dizziness)
- Low patient compliance (skipping more than 3 procedures), refusal to participate in the study
- Exacerbation of the underlying disease during the study
Источник: ClinicalTrials.gov, NCT07075835 · запись обновлена в реестре 11 августа 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (4), вторичных — 2
- Dynamic of lung volumes — 1 month
- Dynamic of lung diffusion capacity — 1 month
- Dynamic of physical activity tolerance — 1 month
- Dynamic of quality of life — 1 month
Цель исследования
This study evaluates enhanced external counterpulsation as a non-pharmacological therapy for patients with severe and moderate ventilation disorders due to chronic lung diseases (chronic obstructive pulmonary disease, bronchial asthma and interstitial lung diseases). The study will include 80 patients with severe (30% \< forced expiratory volume in 1 second \< 49% or lung diffusion capacity \< 40%) and moderate (50% \< forced expiratory volume in 1 second \< 59% or lung diffusion capacity 40-60%) ventilation disorders, who will be divided into 2 groups (the main group and the comparison group). In addition to optimal pharmacological therapy according to the current clinical guidelines of the Russian Ministry of Health, the main group will receive a course of enhanced external counterpulsation. The comparison group will receive only optimal pharmacological therapy (according to the current clinical guidelines of the Russian Ministry of Health). At the time of inclusion in the study and after 1 month, spirometry, bodyplethysmography, lung diffusion capacity, a 6-minute walk test and an assessment of quality of life according to the SF-36 questionnaire will be conducted.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07075835 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.